Nurix Q3 2024 Earnings Report
Key Takeaways
Nurix Therapeutics reported a net loss of $49.0 million, or ($0.67) per share, for the third quarter ended August 31, 2024. The company's cash, cash equivalents and marketable securities were $457.5 million as of August 31, 2024.
Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA.
Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients.
Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology.
Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics.
Nurix
Nurix
Nurix Revenue by Segment
Forward Guidance
Nurix plans to present additional clinical data from the NX-5948 study for patients with CLL by year-end 2024 and anticipates future clinical updates for NX-2127 in 2025.